Antibiotic use in 26 departments of internal medicine in 6 general hospitals in Israel: Variability and contributing factors

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 1, 2008, Pages 196-204

  Shalit, Itamar ^a   Low, Marcelo ^a   Levy, Erez ^a   Chowers, Michal ^a   Zimhony, Oren ^a   Riesenberg, Klaris ^a   Bishara, Jihad ^a   Raz, Raul ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Antibiotic consumption; Drug utilization; Internal medicine departments

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG USE; GENERAL HOSPITAL; HOSPITAL DEPARTMENT; HOSPITALIZATION; HUMAN; INTERNAL MEDICINE; ISRAEL; LOWER RESPIRATORY TRACT INFECTION; MULTIVARIATE ANALYSIS; NEUTROPENIA; PREDICTION; PRESCRIPTION; SCORING SYSTEM; UNIVARIATE ANALYSIS;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG UTILIZATION; FEMALE; HOSPITALS, GENERAL; HUMANS; ISRAEL; MALE; MIDDLE AGED;

EID: 45749112169     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn150     Document Type: Article

References (23)

1. Goldstein FW. Combating resistance in a challenging, changing environment. Clin Microbiol Infect 2007; 13 Suppl 2: 2-6.
2. MacDougall C, Powell JP, Johnson CK et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41: 435-40.
3. Frank U, Kleissle EM, Daschner FD et al. Multicentre study of antimicrobial resistance and antibiotic consumption among 6,780 patients with bloodstream infections. Eur J Clin Microbiol Infect Dis 2006; 25: 815-7.
4. Riedel S, Beekmann SE, Heilmann KP et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007; 26: 485-90.
5. Malhotra-Kumar S, Lammens C, Coenan S et al. Impact of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci among healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet 2007; 369: 482-90.
6. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 441-6.
7. Cook PP, Catrou P, Gooch M et al. Effect of reduction in ciprofloxacin use on prevalence of methicillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect 2006; 64: 348-51.
8. Zillich AJ, Sutherland JM, Wilson SJ et al. Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. Infect Control Hosp Epidemiol 2006; 27: 1088-95.
9. Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005; 365: 579-87.
10. Vander Stichele RH, Elseviers MM, Ferech M et al. Hospital consumption of antibiotics in 15 European countries: Results of the ESAC Retrospective Data Collection (1997-2002). J Antimicrob Chemother 2006; 58: 159-67.
11. WHO Collaborating Centre for Drug Statistics and Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO, 2003.
12. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. 2005. http://www.whocc.no/atcddd/.
13. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-83.
14. MacKenzie FM, Bruce J, Van Looveren M et al. Antimicrobial susceptibility testing in European hospitals: Report from the ARPAC study. Clin Microbiol Infect 2006; 12: 1185-92.
15. Monnet DL, MacKenzie FM, López-Lozano JM et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10: 1432-41.
16. Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-22.
17. Loeffler JM, Garbino J, Lew D et al. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units. Scand J Infect Dis 2003; 35: 843-50.
18. Bantar C, Sartori B, Vesco E et al. A hospitalwide intervention program to optimize the quality of antibiotic use: Impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37: 180-6.
19. Lee NY, Lee HC, Ko NY et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28: 713-9.
20. Grupper M, Sprecher H, Mashiach T et al. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007; 28: 293-8.
21. Schwaber MJ, Navon-Venezia S, Kaye KS et al. Clinical and economic impact of bacteremia with extended-spectrum-β-lactae-producing Enterobacteriaceae. Antimicrob Agents and Chemother 2006; 50 1257-62.
22. De Souza V, MacFarlane A, Murphy AW et al. A qualitative study of factors influencing antimicrobial prescribing by non-consultant hospital doctors. J Antimicrob Chemother 2006; 58: 840-3.
23. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18: 638-56.